Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders.

Ringelstein M, Harmel J, Zimmermann H, Brandt AU, Paul F, Haarmann A, Buttmann M, Hümmert MW, Trebst C, Schroeder C, Ayzenberg I, Kleiter I, Hellwig K, Havla J, Kümpfel T, Jarius S, Wildemann B, Rommer P, Weber MS, Pellkofer H, Röpke L, Geis C, Retzlaff N, Zettl U, Deppe M, Klotz L, Young K, Stellmann JP, Kaste M, Kermer P, Marouf W, Lauda F, Tumani H, Graf J, Klistorner A, Hartung HP, Aktas O, Albrecht P; Neuromyelitis Optica Study Group (NEMOS).

Neurology. 2019 Dec 3. pii: 10.1212/WNL.0000000000008684. doi: 10.1212/WNL.0000000000008684. [Epub ahead of print]

PMID:
31796527
2.

Human Brain Endothelial CXCR2 is Inflammation-Inducible and Mediates CXCL5- and CXCL8-Triggered Paraendothelial Barrier Breakdown.

Haarmann A, Schuhmann MK, Silwedel C, Monoranu CM, Stoll G, Buttmann M.

Int J Mol Sci. 2019 Jan 30;20(3). pii: E602. doi: 10.3390/ijms20030602.

3.

Age-adjusted CSF β2-microglobulin and lactate are increased and ACE is decreased in patients with multiple sclerosis, but only lactate correlates with clinical disease duration and severity.

Haarmann A, Hähnel L, Schuhmann MK, Buttmann M.

J Neuroimmunol. 2018 Oct 15;323:19-27. doi: 10.1016/j.jneuroim.2018.07.001. Epub 2018 Jul 4.

PMID:
30196829
4.

Where mitoxantrone for multiple sclerosis is still valuable in 2018.

Buttmann M.

Eur J Neurol. 2018 Dec;25(12):1400-1401. doi: 10.1111/ene.13787. Epub 2018 Sep 21. No abstract available.

PMID:
30133060
5.
6.

Altered motor plasticity in an acute relapse of multiple sclerosis.

Wirsching I, Buttmann M, Odorfer T, Volkmann J, Classen J, Zeller D.

Eur J Neurosci. 2018 Feb;47(3):251-257. doi: 10.1111/ejn.13818. Epub 2018 Jan 22.

PMID:
29285814
7.

Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis.

Hahn S, Trendelenburg G, Scharf M, Denno Y, Brakopp S, Teegen B, Probst C, Wandinger KP, Buttmann M, Haarmann A, Szabados F, Vom Dahl M, Kümpfel T, Eichhorn P, Gold H, Paul F, Jarius S, Melzer N, Stöcker W, Komorowski L.

J Neuroinflammation. 2017 Jun 23;14(1):123. doi: 10.1186/s12974-017-0900-z.

8.

Pathogenic inflammation in the CNS of mice carrying human PLP1 mutations.

Groh J, Friedman HC, Orel N, Ip CW, Fischer S, Spahn I, Schäffner E, Hörner M, Stadler D, Buttmann M, Varallyay C, Solymosi L, Sendtner M, Peterson AC, Martini R.

Hum Mol Genet. 2016 Nov 1;25(21):4686-4702. doi: 10.1093/hmg/ddw296.

PMID:
28173160
9.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.

Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hümmert MW, Trebst C, Pache F, Winkelmann A, Beume LA, Ringelstein M, Stich O, Aktas O, Korporal-Kuhnke M, Schwarz A, Lukas C, Haas J, Fechner K, Buttmann M, Bellmann-Strobl J, Zimmermann H, Brandt AU, Franciotta D, Schanda K, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Nov 1;13(1):281.

10.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.

Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, Waldman A, Soelberg K, Asgari N, Ringelstein M, Aktas O, Gross N, Buttmann M, Ach T, Ruprecht K, Paul F, Brandt AU; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Nov 1;13(1):282.

11.

Validation of a multiplexing technique to determine the intrathecal, polyspecific antiviral immune response in multiple sclerosis.

Huss A, Buttmann M, Brecht I, Weishaupt A, Otto M, Tumani H.

Expert Rev Mol Diagn. 2016 Dec;16(12):1353-1356. Epub 2016 Oct 31.

PMID:
27759441
12.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Sep 27;13(1):280.

13.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F, Wildemann B, Reindl M; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Sep 26;13(1):279.

14.

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.

Huss AM, Halbgebauer S, Öckl P, Trebst C, Spreer A, Borisow N, Harrer A, Brecht I, Balint B, Stich O, Schlegel S, Retzlaff N, Winkelmann A, Roesler R, Lauda F, Yildiz Ö, Voß E, Muche R, Rauer S, Bergh FT, Otto M, Paul F, Wildemann B, Kraus J, Ruprecht K, Stangel M, Buttmann M, Zettl UK, Tumani H.

J Neurol. 2016 Dec;263(12):2499-2504. Epub 2016 Oct 11.

15.

Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy.

Doppler K, Appeltshauser L, Villmann C, Martin C, Peles E, Krämer HH, Haarmann A, Buttmann M, Sommer C.

Brain. 2016 Oct;139(Pt 10):2617-2630. Epub 2016 Jul 29.

PMID:
27474220
16.

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.

Sadovnick AD, Traboulsee AL, Bernales CQ, Ross JP, Forwell AL, Yee IM, Guillot-Noel L, Fontaine B, Cournu-Rebeix I, Alcina A, Fedetz M, Izquierdo G, Matesanz F, Hilven K, Dubois B, Goris A, Astobiza I, Alloza I, Antigüedad A, Vandenbroeck K, Akkad DA, Aktas O, Blaschke P, Buttmann M, Chan A, Epplen JT, Gerdes LA, Kroner A, Kubisch C, Kümpfel T, Lohse P, Rieckmann P, Zettl UK, Zipp F, Bertram L, Lill CM, Fernandez O, Urbaneja P, Leyva L, Alvarez-Cermeño JC, Arroyo R, Garagorri AM, García-Martínez A, Villar LM, Urcelay E, Malhotra S, Montalban X, Comabella M, Berger T, Fazekas F, Reindl M, Schmied MC, Zimprich A, Vilariño-Güell C.

G3 (Bethesda). 2016 Jul 7;6(7):2073-9. doi: 10.1534/g3.116.030841.

17.

Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.

Buttmann M, Seuffert L, Mäder U, Toyka KV.

Neurology. 2016 Jun 7;86(23):2203-7. doi: 10.1212/WNL.0000000000002745. Epub 2016 May 11.

18.

Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis.

Halbgebauer S, Huss A, Buttmann M, Steinacker P, Oeckl P, Brecht I, Weishaupt A, Tumani H, Otto M.

J Neurol. 2016 May;263(5):954-960. doi: 10.1007/s00415-016-8094-3. Epub 2016 Mar 19.

PMID:
26995358
19.

Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS.

Schrewe L, Lill CM, Liu T, Salmen A, Gerdes LA, Guillot-Noel L, Akkad DA, Blaschke P, Graetz C, Hoffjan S, Kroner A, Demir S, Böhme A, Rieckmann P, ElAli A, Hagemann N, Hermann DM, Cournu-Rebeix I, Zipp F, Kümpfel T, Buttmann M, Zettl UK, Fontaine B, Bertram L, Gold R, Chan A.

J Neuroinflammation. 2015 Dec 16;12:234. doi: 10.1186/s12974-015-0429-y.

20.

Genome-wide significant association with seven novel multiple sclerosis risk loci.

Lill CM, Luessi F, Alcina A, Sokolova EA, Ugidos N, de la Hera B, Guillot-Noël L, Malhotra S, Reinthaler E, Schjeide BM, Mescheriakova JY, Mashychev A, Wohlers I, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Astobiza I, Blaschke P, Boyko AN, Buttmann M, Chan A, Dörner T, Epplen JT, Favorova OO, Fedetz M, Fernández O, García-Martínez A, Gerdes LA, Graetz C, Hartung HP, Hoffjan S, Izquierdo G, Korobko DS, Kroner A, Kubisch C, Kümpfel T, Leyva L, Lohse P, Malkova NA, Montalban X, Popova EV, Rieckmann P, Rozhdestvenskii AS, Schmied C, Smagina IV, Tsareva EY, Winkelmann A, Zettl UK, Binder H, Cournu-Rebeix I, Hintzen R, Zimprich A, Comabella M, Fontaine B, Urcelay E, Vandenbroeck K, Filipenko M, Matesanz F, Zipp F, Bertram L.

J Med Genet. 2015 Dec;52(12):848-55. doi: 10.1136/jmedgenet-2015-103442. Epub 2015 Oct 16.

PMID:
26475045
21.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis.

Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.

PMID:
26362898
22.

Analysis of Varicella-Zoster Virus in Temporal Arteries Biopsy Positive and Negative for Giant Cell Arteritis.

Nagel MA, White T, Khmeleva N, Rempel A, Boyer PJ, Bennett JL, Haller A, Lear-Kaul K, Kandasmy B, Amato M, Wood E, Durairaj V, Fogt F, Tamhankar MA, Grossniklaus HE, Poppiti RJ, Bockelman B, Keyvani K, Pollak L, Mendlovic S, Fowkes M, Eberhart CG, Buttmann M, Toyka KV, Meyer-ter-Vehn T, Petursdottir V, Gilden D.

JAMA Neurol. 2015 Nov;72(11):1281-7. doi: 10.1001/jamaneurol.2015.2101.

23.
24.

[Quadrivalent HPV vaccination does not increase MS risk].

Buttmann M.

MMW Fortschr Med. 2015 Apr 30;157(8):33. doi: 10.1007/s15006-015-3024-3. German. No abstract available.

PMID:
26012676
25.

Oligoclonal bands predict multiple sclerosis in children with optic neuritis.

Heussinger N, Kontopantelis E, Gburek-Augustat J, Jenke A, Vollrath G, Korinthenberg R, Hofstetter P, Meyer S, Brecht I, Kornek B, Herkenrath P, Schimmel M, Wenner K, Häusler M, Lutz S, Karenfort M, Blaschek A, Smitka M, Karch S, Piepkorn M, Rostasy K, Lücke T, Weber P, Trollmann R, Klepper J, Häussler M, Hofmann R, Weissert R, Merkenschlager A, Buttmann M; for GRACE-MS (German-speaking Research Alliance for ChildrEn with Multiple Sclerosis).

Ann Neurol. 2015 Jun;77(6):1076-82. doi: 10.1002/ana.24409. Epub 2015 May 11.

PMID:
25820181
26.

Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling.

Haarmann A, Nowak E, Deiß A, van der Pol S, Monoranu CM, Kooij G, Müller N, van der Valk P, Stoll G, de Vries HE, Berberich-Siebelt F, Buttmann M.

Acta Neuropathol. 2015 May;129(5):639-52. doi: 10.1007/s00401-015-1417-0. Epub 2015 Mar 27.

27.

NFAT1 deficit and NFAT2 deficit attenuate EAE via different mechanisms.

Dietz L, Frommer F, Vogel AL, Vaeth M, Serfling E, Waisman A, Buttmann M, Berberich-Siebelt F.

Eur J Immunol. 2015 May;45(5):1377-89. doi: 10.1002/eji.201444638. Epub 2015 Feb 19.

28.

Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study.

Brickshawana A, Hinson SR, Romero MF, Lucchinetti CF, Guo Y, Buttmann M, McKeon A, Pittock SJ, Chang MH, Chen AP, Kryzer TJ, Fryer JP, Jenkins SM, Cabre P, Lennon VA.

Lancet Neurol. 2014 Aug;13(8):795-806. doi: 10.1016/S1474-4422(14)70141-3. Epub 2014 Jul 6.

29.
30.

Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis.

Lill CM, Schilling M, Ansaloni S, Schröder J, Jaedicke M, Luessi F, Schjeide BM, Mashychev A, Graetz C, Akkad DA, Gerdes LA, Kroner A, Blaschke P, Hoffjan S, Winkelmann A, Dörner T, Rieckmann P, Steinhagen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Buttmann M, Kümpfel T, Kubisch C, Zettl UK, Epplen JT, Zipp F, Bertram L.

Neurogenetics. 2014 May;15(2):129-34. doi: 10.1007/s10048-014-0396-y. Epub 2014 Mar 18.

PMID:
24638856
31.

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.

Zeller D, Reiners K, Bräuninger S, Buttmann M.

J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):707-9. doi: 10.1136/jnnp-2013-306860. Epub 2013 Dec 19. No abstract available.

32.

Case reports of PML in patients treated for psoriasis.

Buttmann M, Stoll G.

N Engl J Med. 2013 Sep 12;369(11):1081. doi: 10.1056/NEJMc1307680. No abstract available.

PMID:
24024862
33.

Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders.

Buttmann M, Kaveri S, Hartung HP.

Trends Pharmacol Sci. 2013 Aug;34(8):445-57. doi: 10.1016/j.tips.2013.05.009. Epub 2013 Jun 21. Review.

PMID:
23791035
34.

MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium, Lill CM, Schjeide BM, Graetz C, Ban M, Alcina A, Ortiz MA, Pérez J, Damotte V, Booth D, Lopez de Lapuente A, Broer L, Schilling M, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Blaschke P, Buttmann M, Chan A, Compston A, Cournu-Rebeix I, Dörner T, Epplen JT, Fernández Ó, Gerdes LA, Guillot-Noël L, Hartung HP, Hoffjan S, Izquierdo G, Kemppinen A, Kroner A, Kubisch C, Kümpfel T, Li SC, Lindenberger U, Lohse P, Lubetzki C, Luessi F, Malhotra S, Mescheriakova J, Montalban X, Papeix C, Paredes LF, Rieckmann P, Steinhagen-Thiessen E, Winkelmann A, Zettl UK, Hintzen R, Vandenbroeck K, Stewart G, Fontaine B, Comabella M, Urcelay E, Matesanz F, Sawcer S, Bertram L, Zipp F.

Brain. 2013 Jun;136(Pt 6):1778-82. doi: 10.1093/brain/awt101.

35.

Treating multiple sclerosis with monoclonal antibodies: a 2013 update.

Deiß A, Brecht I, Haarmann A, Buttmann M.

Expert Rev Neurother. 2013 Mar;13(3):313-35. doi: 10.1586/ern.13.17. Review.

PMID:
23448220
36.

Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk.

Lill CM, Schjeide BM, Graetz C, Liu T, Damotte V, Akkad DA, Blaschke P, Gerdes LA, Kroner A, Luessi F, Cournu-Rebeix I, Hoffjan S, Winkelmann A, Touze E, Pico F, Corcia P, Otaegui D, Antigüedad A, Alcina A, Comabella M, Montalban X, Olascoaga J, Matesanz F, Dörner T, Li SC, Steinhagen-Thiessen E, Lindenberger U, Chan A, Rieckmann P, Hartung HP, Aktas O, Lohse P, Buttmann M, Kümpfel T, Kubisch C, Zettl UK, Epplen JT, Fontaine B, Zipp F, Vandenbroeck K, Bertram L.

J Med Genet. 2013 Mar;50(3):140-3. doi: 10.1136/jmedgenet-2012-101411. Epub 2013 Jan 12. No abstract available.

PMID:
23315543
37.

Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.

Benkert TF, Dietz L, Hartmann EM, Leich E, Rosenwald A, Serfling E, Buttmann M, Berberich-Siebelt F.

PLoS One. 2012;7(12):e52208. doi: 10.1371/journal.pone.0052208. Epub 2012 Dec 20.

38.

Atypical chronic lymphocytic inflammation with pontocerebellar perivascular enhancement responsive to steroids (CLIPPERS), primary angiitis of the CNS mimicking CLIPPERS or overlap syndrome? A case report.

Buttmann M, Metz I, Brecht I, Brück W, Warmuth-Metz M.

J Neurol Sci. 2013 Jan 15;324(1-2):183-6. doi: 10.1016/j.jns.2012.10.017. Epub 2012 Nov 11.

PMID:
23149266
39.

Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis.

Brecht I, Weissbrich B, Braun J, Toyka KV, Weishaupt A, Buttmann M.

PLoS One. 2012;7(7):e40431. doi: 10.1371/journal.pone.0040431. Epub 2012 Jul 9.

40.

Lobular panniculitis and lipoatrophy of the thighs with interferon-ß1a for intramuscular injection in a patient with multiple sclerosis.

Weise G, Hupp M, Kerstan A, Buttmann M.

J Clin Neurosci. 2012 Sep;19(9):1312-3. doi: 10.1016/j.jocn.2011.11.026. Epub 2012 Jun 20.

PMID:
22721889
41.

[New disease-modifying and symptomatic therapies for multiple sclerosis].

Weise G, Buttmann M.

MMW Fortschr Med. 2012 Apr 19;154(7):64-6. Review. German. No abstract available.

PMID:
22558878
42.

Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.

Guckenberger M, Mayer M, Buttmann M, Vince GH, Sweeney RA, Flentje M.

Strahlenther Onkol. 2011 Sep;187(9):548-54. doi: 10.1007/s00066-011-2242-6. Epub 2011 Aug 18.

PMID:
21858417
43.

Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown.

Haarmann A, Deiss A, Prochaska J, Foerch C, Weksler B, Romero I, Couraud PO, Stoll G, Rieckmann P, Buttmann M.

PLoS One. 2010 Oct 21;5(10):e13568. doi: 10.1371/journal.pone.0013568.

44.

Encoding of motor skill in the corticomuscular system of musicians.

Gentner R, Gorges S, Weise D, aufm Kampe K, Buttmann M, Classen J.

Curr Biol. 2010 Oct 26;20(20):1869-74. doi: 10.1016/j.cub.2010.09.045. Epub 2010 Oct 14.

45.

Fluctuating neuromuscular transmission defects and inverse acetazolamide response in episodic ataxia type 2 associated with the novel CaV2.1 single amino acid substitution R2090Q.

Melzer N, Classen J, Reiners K, Buttmann M.

J Neurol Sci. 2010 Sep 15;296(1-2):104-6. doi: 10.1016/j.jns.2010.06.024.

PMID:
20663518
46.

Treating multiple sclerosis with monoclonal antibodies: a 2010 update.

Buttmann M.

Expert Rev Neurother. 2010 May;10(5):791-809. doi: 10.1586/ern.10.38. Review.

PMID:
20420497
47.

Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis.

Heidbrink C, Häusler SF, Buttmann M, Ossadnik M, Strik HM, Keller A, Buck D, Verbraak E, van Meurs M, Krockenberger M, Mehling M, Mittelbronn M, Laman JD, Wiendl H, Wischhusen J.

Brain Behav Immun. 2010 Aug;24(6):975-84. doi: 10.1016/j.bbi.2010.04.003. Epub 2010 Apr 10.

PMID:
20385225
48.

[Therapeutic monoclonal antibodies in clinical neurology].

Buttmann M, Wiendl H.

Nervenarzt. 2010 Jun;81(6):753-64; quiz 765-6. doi: 10.1007/s00115-010-2947-2. Review. German.

PMID:
20232033
49.

Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J.

Cancer Res. 2009 Oct 15;69(20):8058-66. doi: 10.1158/0008-5472.CAN-09-0834. Epub 2009 Oct 13.

50.

Sumoylation of the transcription factor NFATc1 leads to its subnuclear relocalization and interleukin-2 repression by histone deacetylase.

Nayak A, Glöckner-Pagel J, Vaeth M, Schumann JE, Buttmann M, Bopp T, Schmitt E, Serfling E, Berberich-Siebelt F.

J Biol Chem. 2009 Apr 17;284(16):10935-46. doi: 10.1074/jbc.M900465200. Epub 2009 Feb 14.

Supplemental Content

Loading ...
Support Center